A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab
A Single-center, Open-Label, Dose Escalation Study Evaluating the Safety of in Vivo Administration of FEIBA in Congenital Hemophilia A Patients With Inhibitors on Emicizumab
Sponsor: Children's Hospital Los Angeles
This PHASE4 trial investigates Hemophilia A With Inhibitor and is currently ongoing. Children's Hospital Los Angeles leads this study, which shows 7 recorded versions since 2020 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Active Not Recruiting PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE4
-
Apr 2022 — Jul 2024 [monthly]
Active Not Recruiting PHASE4
-
Nov 2021 — Apr 2022 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Nov 2021 [monthly]
Recruiting PHASE4
▶ Show 2 earlier versions
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Jan 2020 — Aug 2020 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Children's Hospital Los Angeles
- Takeda
For direct contact, visit the study record on ClinicalTrials.gov .